Inhibiting tumor angiogenesis is a well-established approach for anticancer therapeutic development. A Disintegrin-like and Metalloproteinase with ThromboSpondin Motifs 5 (ADAMTS5) is a secreted matrix metalloproteinase in the ADAMTS family that also functions as an anti-angiogenic/anti-tumorigenic molecule. Its anti-angiogenic/anti-tumorigenic function is independent from its proteinase activity, but requires its first thrombospondin type 1 repeat (TSR1). However, it is not known if recombinant TSR1 (rTSR1) can function as an anticancer therapeutic. In this report, we expressed and purified a 75-residue recombinant TSR1 polypeptide from E. coli and investigated its ability to function as an anticancer therapeutic in mice. We demonstrate that rTSR1 is present in the blood circulation as well as in the tumor tissue at 15 min post intraperitoneal injection. Intraperitoneal delivery of rTSR1 potently suppressed subcutaneous B16F10 melanoma growth as a single agent, accompanied by diminished tumor angiogenesis, increased apoptosis, and reduced cell proliferation in the tumor tissue. Consistently, rTSR1 dose-dependently induced the apoptosis of cultured human umbilical vein endothelial cells (HUVECs) in a caspase-dependent manner. This work indicates that rTSR1 of ADAMTS5 can function as a potent anticancer therapy in mice. It thus has the potential to be further developed into an anticancer drug.
Introduction
The tumor microenvironment predominantly displays excessive angiogenesis, due to the high level of pro-angiogenic factors present [1] . Angiogenesis is needed not only for the sustained growth of a solid tumor, but also for tumor metastasis [2] . Factors inhibiting angiogenesis have been actively pursued as anticancer therapeutics. Amongst them, endogenous angiogenesis inhibitor proteins have gained much attention owing to their high specificity and low side effects [3, 4] .
A Disintegrin-like and Metalloproteinase with ThromboSpondin Motifs 5 (ADAMTS5) is an extracellular proteoglycanase of the ADAMTS family. It is widely studied for its role in osteoarthritis, as the main aggrecanase that cleaves aggrecans in the articular cartilage [5, 6] . However, contrasting roles for ADAMTS5 have been reported with regards to cancer. While several studies have reported reduced expression of ADAMTS5 in cancers, such as prostate cancer [7] , breast cancer [8] , colorectal cancer [9] , and hepatocellular carcinoma (HCC) [10] , others have reported elevated expression of ADAMTS5 in human glioblastomas [11] . A recent report indicated that high ADAMTS5 expression in colorectal cancer patients correlated with higher levels of lymphatic invasion and lymph node 2 of 10 metastasis [12] . Nevertheless, no significant differences in the overall survival and disease-free survival of these colorectal patients were observed.
We have previously demonstrated that ADAMTS5 functions as an inhibitor of angiogenesis and suppresses xenograft tumor growth in mice [13] . We showed that this anticancer function is independent of the catalytic activity of ADAMTS5, but is mediated by its central ThromboSpondin type 1 repeat domain (TSR1). Stable overexpression of the TSR1 domain alone in B16 melanoma cells suppressed subcutaneous tumor growth in syngeneic mice. We also reported that E. coli produced recombinant TSR1 (rTSR1), but not the C-terminus TSR2 (rTSR2), which inhibits human umbilical vein endothelial cell (HUVEC) tube formation and proliferation in vitro. Additionally, rTSR1 triggers HUVEC apoptosis in the presence of vascular endothelial growth factor (VEGF) [14] . These findings suggest that rTSR1 polypeptide may have the potential to be developed as an anticancer therapeutic.
In this study, we investigated whether rTSR1 can function as an anticancer therapeutic in a mouse xenograft model. We show that intra-peritoneal delivery of rTSR1 potently suppressed subcutaneous B16 melanoma growth in mice. This result establishes that rTSR1, a 75-residue polypeptide from ADAMTS5, warrants further investigation. It has the potential to be developed as an anticancer therapy for melanoma.
Results

Recombinant Type 1 Repeat Domain Induces Caspase-Dependent Apoptosis in Human Umbilical Vein Endothelial Cells
We expressed the His-tagged 75-residue TSR1 domain of ADAMTS5 in E. coli. With the Ni-NTA (Nickel-Nitrilotriacetic acid) column, the expressed rTSR1 was purified as a single band at~10 kDa in an SDS-PAGE and anti-His immunoblot ( Figure 1A ). No significant endotoxin was present in the purified rTSR1 (data not shown). Consistent with our previous report, rTSR1 showed significant pro-apoptotic activity at 500 nM and 1000 nM after 24 h incubation in the presence of VEGF ( Figure 1B ) [14] . Since prominent pro-apoptotic activity was observed at 1000 nM, this concentration was then used for subsequent experiments. The rTSR1 triggered HUVEC apoptosis in a caspase-dependent manner, and the presence of the pan-caspase inhibitor Z-VAD-FMK eliminated rTSR1 (1000 nM)-induced apoptosis ( Figure 1C ).
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Results
Recombinant Type 1 Repeat Domain Induces Caspase-Dependent Apoptosis in Human Umbilical Vein Endothelial Cells
We expressed the His-tagged 75-residue TSR1 domain of ADAMTS5 in E. coli. With the Ni-NTA (Nickel-Nitrilotriacetic acid) column, the expressed rTSR1 was purified as a single band at ~10 kDa in an SDS-PAGE and anti-His immunoblot ( Figure 1A ). No significant endotoxin was present in the purified rTSR1 (data not shown). Consistent with our previous report, rTSR1 showed significant proapoptotic activity at 500 nM and 1000 nM after 24 h incubation in the presence of VEGF ( Figure 1B ) [14] . Since prominent pro-apoptotic activity was observed at 1000 nM, this concentration was then used for subsequent experiments. The rTSR1 triggered HUVEC apoptosis in a caspase-dependent manner, and the presence of the pan-caspase inhibitor Z-VAD-FMK eliminated rTSR1 (1000 nM)-induced apoptosis ( Figure 1C ). 
Recombinant Type 1 Repeat Domain Suppressed the B16F10 Melanoma Growth in Mice
To investigate if rTSR1 can be a potential anticancer drug, the effect of systemically delivered rTSR1 on tumor growth was investigated. A subcutaneous tumor was generated by injecting half a million B16 melanoma cells into the dorsal flank of mice. On the same day, buffer or 200 µg of rTSR1 was injected intraperitoneally (IP) to each mouse to the control group and rTSR1 treatment group, respectively. Subsequently, rTSR1 was delivered to each mouse on alternate days. Tumor nodules were visible on day seven post-cell inoculation. Treatment with rTSR1 led to a significant reduction of tumor growth when compared to the control mice (Figure 2A) . At the end of the experiment (on day 15 post-cell inoculation), tumor nodules were harvested, and significantly reduced tumor weights were observed ( Figure 2B,C) . Notably, rTSR1-treated mice had an obviously reduced peri-tumor vasculature, consistent with the anti-angiogenic activity of rTSR1 ( Figure 2D ). These data demonstrate that rTSR1 can function as an anticancer therapy as a single agent in mice, likely by restricting angiogenesis.
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Discussion
In this work, we demonstrate that systemically delivered rTSR1 of ADAMTS5 via IP injection potently suppressed distant subcutaneous melanoma growth in mice. This drug delivery approach is clinically applicable for human cancer treatment. We show that the IP-delivered rTSR1 is already present in large amounts in the tumor tissues at 15 min post-peptide injection. These results indicate that rTSR1 can potentially be further developed into an anticancer drug.
Since the rTSR1 polypeptide is only 75 residues long, it can in principle also be chemically synthesized. The pro-apoptotic activity of rTSR1 is stable between the different batches of the recombinant polypeptides produced. Since bacteria-produced rTSR1 contains no post-translational modifications, and the peptide is produced from insoluble inclusion bodies, the peptide sequence, as well as its spontaneously-formed tertiary structures after purification, is presumed to play a critical role for its anticancer and pro-apoptotic functions.
Angiogenesis inhibitor proteins and polypeptides are reported to have minimum adverse effect on the quiescent vessel of a healthy individual, but they specifically inhibit pathological angiogenesis. This is a property that makes them as attractive candidates for anticancer drugs [15] . These antiangiogenic proteins/polypeptides provide a source for designing and developing novel antiangiogenic agents. As new endogenous angiogenesis inhibitors are continuously being discovered, novel anticancer agents are promising [16] . Thrombospondin-1 (TSP-1) is the first endogenous angiogenesis inhibitor protein identified, and its TSR domains in recombinant forms have been shown to have anticancer activity in mice [17] . Several members of the human ADAMTS family have been reported to have anti-angiogenic and anti-tumorigenic functions [18] . However, not all TSRs are anti-angiogenic, and unique sequences and structures are likely the determinants for a TSR to harbor anti-angiogenic functions.
While HUVECs underwent apoptosis upon rTSR1 treatment, cancer cells, both B16F10 melanoma and 4T1 breast cancer cells, were found to be insensitive to rTSR1 under cell culture conditions ( Figure S1 and data not shown, respectively). Hence, rTSR1 most likely triggered tumor cell apoptosis in mice through its anti-angiogenic activity, which indirectly led to the induction of apoptosis in tumor cells (Figures 2 and 3) . Similarly, the suppression of tumor cell proliferation under rTSR1 treatment in mice is likely an indirect effect of tumor angiogenesis inhibition. Previously, Miao et al. reported that the recombinant three TSR domains of human TSP-1 (3TSR/hTSP-1) produced from Drosophila S2 cells inhibited tumor growth by suppressing tumor angiogenesis, with the concurrent observation of increased tumor cell apoptosis and reduced tumor cell proliferation [17] . Hence, ADAMTS5 TSR1 produced from E. coli without any post-translational modifications seems to have a similar impact on tumors in mice, although the underlining molecular mechanisms and signaling pathways involved may not be the same.
The fact that the IP-delivered rTSR1 is detectable in serum and tumor lysate at 15 min postinjection suggests a fast and efficient distribution of this polypeptide into tumors. However, the in- Figure 6 . IP-injected rTSR1 reached the tumor. Immunoblot of serum and tumor lysate displayed band at~10 kDa, corresponding to the molecular weight of rTSR1. The band is observed both in serum (A) and with the whole tumor lysate (B) from mice that received rTSR1 only. The rTSR1 input is used as the positive control. M1 to M3 refer to mouse 1 to mouse 3.
Angiogenesis inhibitor proteins and polypeptides are reported to have minimum adverse effect on the quiescent vessel of a healthy individual, but they specifically inhibit pathological angiogenesis. This is a property that makes them as attractive candidates for anticancer drugs [15] . These anti-angiogenic proteins/polypeptides provide a source for designing and developing novel anti-angiogenic agents. As new endogenous angiogenesis inhibitors are continuously being discovered, novel anticancer agents are promising [16] . Thrombospondin-1 (TSP-1) is the first endogenous angiogenesis inhibitor protein identified, and its TSR domains in recombinant forms have been shown to have anticancer activity in mice [17] . Several members of the human ADAMTS family have been reported to have anti-angiogenic and anti-tumorigenic functions [18] . However, not all TSRs are anti-angiogenic, and unique sequences and structures are likely the determinants for a TSR to harbor anti-angiogenic functions.
The fact that the IP-delivered rTSR1 is detectable in serum and tumor lysate at 15 min post-injection suggests a fast and efficient distribution of this polypeptide into tumors. However, the in-vivo stability of rTSR1 is unclear at this stage. Nevertheless, the injection frequency of once every two days was sufficient to inhibit B16F10 tumor growth in mice.
Materials and Methods
Recombinant Type 1 Repeat Domain Production and Purification
The TSR1 domain of human ADAMTS5 corresponds to amino acid residues 567-622. The cDNA sequence corresponding to residues 561-634, which include the surrounding sequences on both the Nand C-terminus of TSR1, were codon-optimized for E. coli expression and cloned into a pET30a vector with a N-terminal His-tag (GenScript, Piscataway, NJ, USA). The plasmid construct was transformed into E. coli BL21 (DE3) under kanamycin selection. Auto-induction media was used to express rTSR1, and proteins were extracted from insoluble fraction using TRIS buffer containing 8 M urea and with a pH of 8.0. Purification was proceeded using a one-step Ni-NTA column. Fractions were pooled, concentrated, dialyzed, and analyzed by SDS-PAGE and Western blot. Protein concentration was determined with a Bradford protein assay.
Cell Culture
Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from PromoCell (Cat # C-12200, Heidelberg, Germany), and cultured in EndoGRO-LS complete medium (Millipore, Millipore Corporation, Billerica, MA, USA) on 0.2% gelatin-coated culture flasks at 37 • C in a humidified incubator with 5% CO 2 (Thermo Scientific, Singapore). The HUVECs of passages three to seven were used for the experiments. B16F10 melanoma cells and 4T1 breast cancer cells were cultured in Dulbecco's modified eagle medium (DMEM) -high glucose (GE Life sciences, Pittsburgh, PA, USA)) with 10% fetal bovine serum.
Apoptosis Determination by IncuCyte ZOOM Live-Cell Analysis System
HUVECs were plated in 96-well, flat, clear-bottom, tissue culture grade microplates at the cell density of 5 × 10 3 cells/well. The following day, the cells were starved in basal media with 2% FBS for 4 h prior to the experiment. Fluorescent conjugated caspase 3/7 substrate (Cat # 4440, Essen Biosciences Ltd., Ann Arbor, MI, USA) was reconstituted in media at the final concentration of 5 µM. Apoptosis was monitored with IncuCyte ZOOM instrument (Essen Biosciences), which was maintained inside a humidified incubator with 5% CO 2 at 37 • C. Every 1 h for 24 h, phase contrast and green fluorescence channel images were collected from each well. Each well was divided into four quadrants, and every quadrant was imaged using a 10× objective lens and analyzed using IncuCyte ZOOM software, version 2016A. The pan-caspase inhibitor Z-VAD-FMK is from R&D systems (Cat # FMK001, Minneapolis, MN, USA).
Western Blot
Mice serum and excised tumor lysate were subjected to Western blot analysis. The total protein of 10 µg/lane was resolved with 15% SDS-PAGE and transferred to a nitrocellulose membrane (Cat # 170-4270, Bio-Rad, Philadelphia, PA, USA) using the Trans-Blot Turbo TM Transfer system (Bio-Rad). The membrane was blocked with 3% skimmed milk for 1 h at room temperature. This was followed by overnight incubation with an anti-His antibody (Cat # A00186-100, GenScript, Piscataway, NJ, USA), probing with the respective fluorescent tagged secondary antibody (Cat # 926-32212, LICOR Inc., Lincoln, NE, USA), and visualization using a fluorescent imaging system (Odyssey CLx, LI-COR Inc.).
Immunohistochemistry
Paraffin-embedded tissue sections of 5 µm thickness were de-paraffinized by heating at 60 • C for 15 min followed by Histochoice clearing agent (Cat # H2779, Sigma, St. Louis, MO, USA) for two changes, 5 min each. Then tissues were rehydrated in a series of alcohol (100%, 90%, 80%, and 70% ethanol in double-distilled water) followed by PBS for 5 min. Using 2100-Retriever (Electron Microscopy Sciences, Hatfield, PA, USA), antigen retrieval was performed in sodium citrate buffer (pH 6.0), and then sections were blocked using 3% bovine serum albumin for 1 h in a humidified chamber at room temperature, followed by incubation with anti-endomucin (Cat # SC65495, Santa Cruz, CA, USA) anti-PCNA (Cat # 10205-2-AP, Proteintech, Rosemont, IL, USA), or cleaved caspase-3 (Cat # 9661S, Cell Signaling, Danvers, MA, USA) antibodies at 4 • C overnight. For double staining, tumor sections were incubated with two antibodies together. The next day, the non-specifically bound antibody was washed with 0.1% tween20 in PBS and treated with the respective Alexa fluor 546/488 (Cat # A21206/A11081, Invitrogen, Rockford, IL, USA) for 2 h at room temperature. Apoptotic cells were stained using an in-situ cell death detection kit (Roche, Cat # 11684795910, Basel, Switzerland), based on the TUNEL (TUNEL). The nucleus was counter-stained with DAPI. Fluorescence images were captured using a fluorescence microscope (Zeiss AxioImager M2, Oberkochen, Germany).
Xenograft Mouse Tumorigenesis Assay
Adult (7-to 8-week-old) female C57BL/6J mice were used in this study. Institution animal care and use committee approval was followed for animal care and experimentation (IACUC; protocol # R16-032, Singapore). Briefly, on day 0, B16F10 mouse melanoma cells (5 × 10 5 ) in 100 µL of PBS were injected into the dorsal flank of the mouse. Mice in the control and rTSR1-treated groups were intra-peritoneally (IP) injected with buffer and 200 µg rTSR1/mouse respectively, on alternate days from day 0. Buffers and rTSR1 were filter-sterilized using 0.22 µm filters prior to injection. All mice were monitored daily for their health status, and visible tumor dimensions were measured from seven days post-injection, using a digital caliper, until day 15 post-injection. Tumor volume was determined using the formula Volume = [width 2 (W 2 ) × length (L)/2] mm 3 , where the length is the largest dimension of the tumor and width is the perpendicular dimension. The mice were euthanized using CO 2 asphyxiation, and blood samples were drawn for serum isolation. Tumor xenografts were surgically excised, with half of the excised tumors used for immunoblot analysis and the other half fixed in 10% formalin and used for paraffin blocking and sectioning.
Mice Serum Isolation
For serum isolation, 500 µL of blood was drawn from mice through cardiac puncture 15 min after rTSR1 IP injections. From each group (control and rTSR1 treated), blood was collected from three different mice and allowed to clot while standing for 2 h, and serum was separated by centrifugation and then subjected to Western blot analysis.
Conclusions
In this work, we presented data indicating that rTSR1 of ADAMTS5 functions as an effective anticancer therapeutic in mice. The tumor suppressive activity of rTSR1 correlated with its inhibition of tumor angiogenesis in vivo and induction of HUVEC apoptosis in vitro. Future studies to understand the molecular mechanisms of its endothelial specific pro-apoptotic activity and additional optimization and modification of the 75 residue polypeptide will help to develop rTSR1 for clinical applications in human cancer. 
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